Get the latest news, insights, and market updates on ONC (BeOne Medicines AG). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
BeOne Medicines to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., February 17, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: Feb 17, 2026 - $ONC
Bernstein Remains a Buy on BeOne Medicines AG (ONC)
BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from Bernstein reiterated a Buy rating on the stock with a $414 price target. Earlier, on February 4, Barclays also reiterated a Buy rating on BeOne Medicines AG (NASDAQ:ONC) and raised the price target from […] Feb 13, 2026 - $ONC
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
SAN CARLOS, Calif., February 11, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. Feb 11, 2026 - $ONC
A Look At BeOne Medicines (ONC) Valuation After Recent Mixed Short Term Returns
BeOne Medicines (ONC) has been drawing investor attention after a recent stretch of mixed short term returns, with a 1 day decline and flat performance over the past week alongside gains over the past month. See our latest analysis for BeOne Medicines. At a share price of $340.38, BeOne Medicines has paired a 9.44% year to date share price return with a 51.29% total shareholder return over the past year. This points to momentum that has been stronger for long term holders than for recent... Feb 2, 2026 - $ONC
Should InSysBio Modeling Partnership Expansion Shape How Investors View BeOne Medicines’ (ONC) Oncology Strategy?
In the past week, InSysBio announced an extension of its collaboration with BeOne Medicines, applying mechanistic translational modeling to refine starting doses, step-up regimens, and dose-escalation design to reduce cytokine release syndrome risk in clinical trials. Alongside this, BeOne Medicines highlighted advanced oncology assets such as BRUKINSA and sonrotoclax, underscoring how external modeling partnerships are being used to support a broad pipeline of 15 new molecular entities... Feb 2, 2026 - $ONC
BeOne Medicines Deepens InSysBio Partnership To Refine Oncology Trial Risk
BeOne Medicines, ticker NasdaqGS:ONC, extended its collaboration with InSysBio to apply mechanistic translational modeling to clinical trial design. The expanded partnership focuses on refining dosing regimens and addressing safety concerns such as cytokine release syndrome. The companies aim to use advanced modeling tools to inform future trial planning and support BeOne Medicines' drug development programs. For you as an investor, this move connects directly to how BeOne Medicines runs... Feb 2, 2026 - $ONC
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development
BeOne Medicines AG (NASDAQ:ONC) is one of the best healthcare stocks to buy for 2026. On January 13, at the 44th Annual J.P. Morgan Healthcare Conference, BeOne Medicines AG (NASDAQ:ONC) reiterated significant progress in its pipeline development. BRUKINSA, a tyrosine kinase inhibitor, has achieved 74% six-year progression-free survival, compared with 32% with bendamustine plus rituximab, […] Jan 31, 2026 - $ONC
Citizens Highlights BeOne Medicines’ (ONC) $3.8B Revenue Potential for 2025
BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best high growth European stocks to buy. On January 7, Citizens reaffirmed its Market Outperform rating and $396 price target for BeOne Medicines Ltd. (NASDAQ:ONC), citing strong effectiveness results from a Phase 3 trial in gastric cancer patients. BeOne Medicines Ltd. (NASDAQ:ONC) and Jazz Pharmaceutics shared further findings […] Jan 30, 2026 - $ONC
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple